A Case of Tumor Lysis Syndrome in a Patient with Pancreatic Adenocarcinoma Treated with Low-Dose Gemcitabine

BACKGROUNDTumor lysis syndrome (TLS) is a common adverse consequence of treatment of high-grade hematologic malignancies that has been known to occur rarely in some solid tumors, including small cell lung cancer, breast cancer, colorectal cancer, neuroblastoma, ovarian cancer, and hepatocellular car...

Full description

Saved in:
Bibliographic Details
Published in:The Ochsner journal 2015, Vol.15 (4), p.455-456
Main Authors: Brinton, Taylor, Yousuf, Tariq, Steinecker, Gary, Rydel, James
Format: Report
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUNDTumor lysis syndrome (TLS) is a common adverse consequence of treatment of high-grade hematologic malignancies that has been known to occur rarely in some solid tumors, including small cell lung cancer, breast cancer, colorectal cancer, neuroblastoma, ovarian cancer, and hepatocellular carcinoma. CASE REPORTWe present a case of TLS in a patient with pancreatic adenocarcinoma treated with one small dose of gemcitabine. To our knowledge, this phenomenon has only been described once prior in the medical literature and never with a reduced dose of chemotherapy. CONCLUSIONThis case reveals the need for heightened awareness of TLS in patients with solid tumors, especially in patients with pancreatic adenocarcinoma.
ISSN:1524-5012